New combination therapy for renal cell (kidney) cancer after surgery

For people diagnosed with renal cell (kidney) cancer, surgery (called a nephrectomy) is often the first major step in treatment. Even after surgery, some patients face a risk of cancer coming back.

New research presented at the ASCO Genitourinary Cancers Symposium 2026 offers encouraging news: adding a newer targeted therapy to standard treatment may help reduce that risk.

What was studied?

In a large phase III clinical trial called LITESPARK-022, researchers looked at whether combining two treatments could improve outcomes:

• pembrolizumab (an immunotherapy already used after surgery)
• belzutifan (a newer targeted therapy)

More than 1,800 patients participated. All had renal cell (kidney) cancer that had been removed with surgery, but were considered at intermediate-high or high risk of recurrence.

Patients were randomly assigned to receive:

• Pembrolizumab plus belzutifan, or
• Pembrolizumab plus a placebo (inactive pill)

What did the study find?

After about 2 years of follow-up, the results showed a meaningful benefit for the combination approach:

• The combination reduced the risk of cancer returning or death by 28%
• At 24 months:
  • 80.7% of patients receiving both drugs were cancer-free
  • Compared with 73.7% of those receiving pembrolizumab alone

This measure is called disease-free survival (DFS), meaning how long patients live without their cancer coming back. While it’s still too early to know if patients live longer overall, early trends suggest a possible benefit.

Why this matters

Until recently, pembrolizumab alone had become the standard treatment after surgery for higher-risk renal cell (kidney) cancer.

This study is important because:

• It’s the first trial in this setting to show that a combination treatment works better than a single drug
• Experts say it could change the standard of care for some patients

What about side effects?

Like most cancer treatments, adding another drug can increase side effects.

In this study:

• 52% of patients on the combination had more serious side effects
• Compared with 30% on pembrolizumab alone

The most common serious side effects included:

• Low red blood cell counts (anemia)
• Changes in liver enzymes
• Low oxygen levels (hypoxia)

Importantly:

• Treatment completion rates were similar in both groups
• Serious treatment-related deaths were rare (0.3%)
• No unexpected new safety concerns were found

A shift in how kidney cancer is treated?

These results are especially interesting because past combination approaches in this setting haven’t always worked well. Belzutifan targets a pathway involved in how tumors grow blood vessels, but it works differently from older drugs, potentially explaining why this approach is more effective.

What this means for patients

If you’ve had surgery for renal cell (kidney) cancer and are at higher risk of recurrence, this research may open the door to new treatment options in the near future.

However, it’s important to remember:

• This combination is still being evaluated and may not yet be widely available for all patients
• The right treatment depends on your individual situation, including your overall health and risk level

Questions to ask your care team

If this research is relevant to you, consider asking:

• Am I at high risk for my cancer coming back?
• Is pembrolizumab alone appropriate for me?
• Are there clinical trials or newer combination treatments I should consider?
• How do the potential benefits compare with the side effects?

As research continues, patients and care teams may soon have more tools to help keep renal cell (kidney) cancer from returning.

Outcomes4Me is here to help you better understand your diagnosis and treatment options. You deserve clear, trustworthy information at every step.